Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized biomarker study of bevacizumab plus carboplatin-based chemotherapy in advanced non-squamous non-small cell lung cancer
2008-000662-23Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoint: Correlation of biomarkers with investigator-assessed response rate. Started Jun 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-000662-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000662-23.